“As the plan is released, the problems of orientation and financial investment are now resolved. However, to cultivate a billion-dollar pharmaceutical company, many supporting policies are still pending.†Yu Mingde, President of the Chinese Pharmaceutical Enterprise Management Association, accepted on January 8th. According to an interview conducted by the Southern Metropolis Daily reporters. The "Bio-industry Development Plan" issued by the State Council in the past few days caused the domestic bio-pharmaceutical sector to soar for two days and began to decline overall yesterday. According to this plan, the average annual growth rate of China's bio-industry output will remain above 20% from 2013 to 2015; by 2020, the development of the bio-industry will become the pillar industry of the national economy. "From 2013 to 2015, a group of enterprises with an annual output value exceeding 10 billion yuan will be formed in the fields of bio-medicine and bio-agriculture."
Annual average increase of 20% is not a big problem
With regard to the decline in the biomedical sector yesterday, market analysts believe that it is the result of the investor’s acceptance. However, there are also some people in the pharmaceutical industry who have begun to question the basis for the surge in the sector.
According to the requirements of the "Biological Industry Development Plan", the bio-industry must develop into a pillar industry of the national economy by 2020, which means that the bio-industries must form a group of world-class innovative companies before that. However, according to Feng Fei, Minister of Industry and Economic Research of the Development Research Center of the State Council, the gap between the basic research of China's bio-industry and developed countries is about five years, and the gap between industrialization is more than 15 years, and there is a trend of further expansion.
In addition, the average annual growth rate of the output value of the bio-industry will reach 20% or more in the next three years. Whether this goal can be achieved has also become a hot issue in the industry.
As a matter of fact, the 20% growth rate is only slightly more difficult when it comes to the production of pharmaceutical sub-sectors. According to the National Pharmaceutical Economic Information Research Institute of the State Food and Drug Administration in 2012, the total output value of the pharmaceutical industry in 2012 will only maintain a 20% increase. This growth rate has significantly slowed by 7 percentage points compared with the growth rate of 27.19% in 2011.
However, Yu Mingde believes that the bio-pharmaceutical industry does not have a problem of maintaining an average annual growth rate of 20%. Because, "Over the past 15 years, the domestic biopharmaceutical industry has been growing at a rate of over 20% for 15 consecutive years."
Supporting policies are yet to be introduced
In Ming De's view, the current series of supporting policies are those that truly affect or hinder the bio-industries from achieving the above-mentioned planning goals.
He believes: "Only low prices must be replaced, and blindly lower than the price, can only be the destruction of these goals. Encouraging biotechnology innovation drug insurance policy must also be adjusted, if the domestic research and development of new biological drugs in the market Shortly after being able to enjoy Medicare reimbursement, that’s the biggest support for new drug innovation. In addition, the issue of delay in registration approval for new drugs must also be taken into account. New drug approvals need to focus on safety and effectiveness, but if a new drug is in all aspects After meeting the listing requirements, it will take another 10 years before it can be listed. It must be changed."
Some companies interviewed Nandu reporters and called on the government to create an environment for the development of bio-industries, provide better public services and help companies develop market demand. In its view, "the field of bio-innovative medicine, there is still much room for improvement in terms of R&D services and inspection services."
Middle Capacity Black Garlic Machine
Middle Capacity, such as 200kg Black Garlic Machine is also very popular.It's output is about 100kg black garlic for each batch prodcution.
Black Garlic Machine is widely used for making whole black garlic, solo black garlic and so on. It's process cycle is about 20days for one batch.
We use anhyrous fermenting technology to make black garlic so we don't need to prepare water pipe .We just need to control fermenting time and temperature.
Black Garlic Fermentation Machine, Black Garlic Maker Machine,Industrial Black Garlic Fermenter Machine,Black Garlic Fermenting Machine
Zhucheng Tongxi Commercial And Trade Co.,Ltd. , https://www.blackgarlicgroup.com